SCHEMBL1409807

SCHEMBL1409807

CCCCC(C)CCC=O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.52
ALDH1A1 P00352 2/20 0.43
FAAH O00519 2/20 0.43
TRPV1 Q8NER1 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ACE2 Q9BYF1 1/20 0.41
ADH1B P00325 3/20 0.38
ADH1C P00326 3/20 0.38
ADH1A P07327 3/20 0.38
ADH7 P40394 3/20 0.38
ADH4 P08319 2/20 0.38
CYP3A4 P08684 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HIF1A Q16665 1/20 0.35
LMNA P02545 1/20 0.35
EPHX1 P07099 1/20 0.34
SLC15A1 P46059 1/20 0.34
CTSK P43235 1/20 0.34
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1410356 0.93 TSHR (0.52) TSHRALDH1A1FAAHTRPV1SMN1; SMN2
SCHEMBL27577002 0.91 TSHR (0.56) TSHRALDH1A1FAAHTRPV1ACE2
SCHEMBL1783042 0.91 TSHR (0.56) TSHRALDH1A1FAAHTRPV1ACE2
SCHEMBL13309278 0.91 TSHR (0.56) TSHRALDH1A1FAAHTRPV1ACE2
SCHEMBL11358374 0.91 TSHR (0.56) TSHRALDH1A1FAAHTRPV1ACE2
SCHEMBL13309277 0.91 TSHR (0.56) TSHRALDH1A1FAAHTRPV1ACE2
SCHEMBL28194813 0.91 TSHR (0.56) TSHRALDH1A1FAAHTRPV1ACE2
SCHEMBL1410276 0.91 TSHR (0.59) TSHRALDH1A1FAAHTRPV1SMN1; SMN2
SCHEMBL1786680 0.88 TSHR (0.58) TSHRALDH1A1FAAHTRPV1SMN1; SMN2
SCHEMBL10736358 0.87 LMNA (0.46) TSHRALDH1A1FAAHTRPV1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116375567-A Method for manufacturing multi-branched high carbonic acid 浙江信汇新材料股份有限公司 2023-07-04 CN claimed
EP-3655466-A2 STABILIZED BIOFILLER PARTICLES AND POLYMER COMPOSITIONS INCLUDING THE SAME Xinova, LLC (US) 2020-05-27 EP claimed
CN-110669107-A Antibacterial peptide and preparation method thereof 上海医药工业研究院 2020-01-10 CN claimed
EP-0074123-B1 A PROCESS FOR PRODUCING A SINGLE CELL PROTEIN MATERIAL (SCP), SCP AND BIOLOGICALLY PURE CULTURE OF YEAST PHILLIPS PETROLEUM COMPANY (US) 1986-04-30 EP claimed
EP-4365159-B1 ORGANOHALOGEN COMPOUND HAVING CONJUGATED DOUBLE BOND, PROCESS FOR PREPARING ACETATE COMPOUND AND ALCOHOL COMPOUND THEREOF, AND COMPOUND USED TO SYNTHESIZE THE ORGANOHALOGEN COMPOUND SHINETSU CHEMICAL CO (JP) 2025-12-03 EP disclosed
US-12246310-B2 Processes for recovery of rhodium from a hydroformylation process DOW TECHNOLOGY INVESTMENTS LLC (US) 2025-03-11 US disclosed
EP-4054762-B1 PROCESSES FOR RECOVERY OF RHODIUM FROM A HYDROFORMYLATION PROCESS DOW TECHNOLOGY INVESTMENTS LLC (US) 2024-12-18 EP disclosed
US-20240174701-A1 ORGANOHALOGEN COMPOUND HAVING CONJUGATED DOUBLE BOND, PROCESS FOR PREPARING ACETATE COMPOUND AND ALCOHOL COMPOUND THEREOF, AND COMPOUND USED TO SYNTHESIZE THE ORGANOHALOGEN COMPOUND SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-05-30 US disclosed
WO-2024100391-A2 NEW ANTIBACTERIAL PRODUCTS UNIVERSITY OF LIVERPOOL (GB) 2024-05-16 WO disclosed
EP-4365159-A1 ORGANOHALOGEN COMPOUND HAVING CONJUGATED DOUBLE BOND, PROCESS FOR PREPARING ACETATE COMPOUND AND ALCOHOL COMPOUND THEREOF, AND COMPOUND USED TO SYNTHESIZE THE ORGANOHALOGEN COMPOUND Shin-Etsu Chemical Co., Ltd. (JP) 2024-05-08 EP disclosed
CN-117924017-A Organic halogen compound having conjugated double bond, method for preparing acetate and alcohol derivative thereof, and compound for synthesizing the compound 信越化学工业株式会社 2024-04-26 CN disclosed
CN-110669107-B Antibacterial peptide and preparation method thereof 上海医药工业研究院 2024-04-02 CN disclosed
US-5998635-A CATALYTIC CYCLIZATION AN ALDEHYDE WITH A KETENE TAKASAGO INTERNATIONAL CORPORATION (JP) 1999-12-07 US disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
EP-0583971-A1 Piperidine derivatives SANKYO COMPANY LIMITED (JP) 1994-02-23 EP disclosed
EP-0251827-B1 NEW CYCLIC ETHER DERIVATIVES, THEIR PREPARATION AND THEIR USE Sankyo Company Limited (JP) 1993-09-15 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
US-4891363-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY LIMITED (JP) 1990-01-02 US disclosed
EP-0251827-A2 New cyclic ether derivatives, their preparation and their use Sankyo Company Limited (JP) 1988-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174701-A1 ORGANOHALOGEN COMPOUND HAVING CONJUGATED DOUBLE BOND, PROCESS FOR PREPARING ACETATE COMPOUND AND ALCOHOL COMPOUND THEREOF, AND COMPOUND USED TO SYNTHESIZE THE ORGANOHALOGEN COMPOUND ADH5, ADH1C, ADH1A TSHR 911/4885ALDH1A1 16/4885FAAH 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.